Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) Meeting Abstract
| Authors: | Tannir, N. M.; McDermott, D. F.; Escudier, B.; Hammers, H. J.; Aren, O. R.; Plimack, E. R.; Barthelemy, P.; Neiman, V.; George, S.; Porta, C.; Powles, T.; Donskov, F.; Grimm, M. O.; Amin, A.; Tykodi, S. S.; Tomita, Y.; Rini, B. I.; McHenry, M. B.; Saggi, S. S.; Motzer, R. J. |
| Abstract Title: | Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) |
| Meeting Title: | 2020 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2020 Feb 13-15 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-02-20 |
| Language: | English |
| ACCESSION: | WOS:000529525900612 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.6_suppl.609 |
| Notes: | Meeting Abstract: 609 -- Source: Wos |
